Global Blood Therapeutics is initiating a Phase 2a clinical trial to assess its oral drug GBT440, an investigational hemoglobin modifier, as a daily treatment for idiopathic pulmonary fibrosis (IPF) and hypoxemia. Hypoxemia, or low blood oxygen levels, results in an insufficient amount of oxygen reaching the tissues (hypoxia). It is a leading cause of clinical decline in IPF…
Phase 2a Study to Evaluate Drug for IPF That Might Improve Blood Oxygen Levels
https://www.youtube.com/watch?v=qLrR8QNa-E4 Pulmonary fibrosis is a lung condition that causes scarring of the lung tissue which results in difficulty breathing. With this video shared by the Royal Society of Medicine, listen in on a lecture by Dr. Melissa Wickremasinghe about living with pulmonary fibrosis and why the disease…
https://www.youtube.com/watch?v=sE9RG_srEBY Pulmonary fibrosis is a lung condition that causes scarring of the lung tissue, which results in difficulties in breathing. With this video, shared by the Royal Society of Medicine, you can watch a lecture by Julia Bott who talks about the benefits of…
Bellerophon Therapeutics recently announced that the Phase 3 INOvation-1 clinical trial evaluating the safety and efficacy of the INOpulse delivery of nitric oxide (NO) in patients with pulmonary arterial hypertension (PAH) has enrolled its first patient. In addition, the company is developing two other INOpulse devices, which may be used to treat patients…
Pulmonary fibrosis is a serious lung disease that causes scarring of the lungs, making it harder for patients to breathe properly. There is currently no known cure available, but there are several treatment options that help patients to cope better with the disease and ease PF symptoms. Among these, is…
As a serious, rare and deathly disease with no known cure, pulmonary fibrosis research is always evolving in an attempt to discover new treatment options, medicines or therapies that can help improve PF patients life and extend life expectancy. Researchers and doctors are in constant work to develop treatment…
Circulating levels of two biomarkers — matrix metalloproteinase-7 (MMP-7) and Krebs von den Lungen-6 (KL-6) — may be effective predictors of disease progression and survival in patients with idiopathic pulmonary fibrosis (IPF), according to the study, “Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease…
https://www.youtube.com/watch?v=IHMy1kOoAm8 Pulmonary fibrosis is a lung condition that causes scaring of the lung tissue which results in difficulties in breathing. In this video, shared by the Royal Society of Medicine, you can watch a lecture by Dr. Sharon Chadwick where she shares some tips on…
Pulmonary fibrosis is a disease that affects the respiratory system by the thickening and stiffening of lung tissue, which ends up as scar tissue.  In cases when physicians are unable to identify the root cause of the disease, it is called idiopathic pulmonary fibrosis. There is no single test that is able to…
Auto-immunity may have a role in the development of fibrotic idiopathic interstitial pneumonias (fIIP), a disease once thought to result solely from environmental factors. New research suggests a possible genetic link, associating two variants of the human leukocyte antigen (HLA) allele to an increased risk of fIIP. The study, “Genome-wide…
